KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Petmed Express (PETS) Gains from Sales and Divestitures (2018 - 2022)

Petmed Express' Gains from Sales and Divestitures history spans 5 years, with the latest figure at $99000.0 for Q1 2022.

  • For Q1 2022, Gains from Sales and Divestitures fell 21.43% year-over-year to $99000.0; the TTM value through Mar 2022 reached $99000.0, down 21.43%, while the annual FY2022 figure was $99000.0, 21.43% down from the prior year.
  • Gains from Sales and Divestitures reached $99000.0 in Q1 2022 per PETS's latest filing, down from $126000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $126000.0 in Q1 2021 to a low of $114.0 in Q1 2018.
  • Average Gains from Sales and Divestitures over 5 years is $82822.8, with a median of $99000.0 recorded in 2022.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 101654.39% in 2019, then tumbled 37.07% in 2020.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $114.0 in 2018, then soared by 101654.39% to $116000.0 in 2019, then crashed by 37.07% to $73000.0 in 2020, then soared by 72.6% to $126000.0 in 2021, then decreased by 21.43% to $99000.0 in 2022.
  • Per Business Quant, the three most recent readings for PETS's Gains from Sales and Divestitures are $99000.0 (Q1 2022), $126000.0 (Q1 2021), and $73000.0 (Q1 2020).